Related Experiment Video

Updated: Jun 25, 2026

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies
10:38

Observational Study Protocol for Repeated Clinical Examination and Critical Care Ultrasonography Within the Simple Intensive Care Studies

Published on: January 16, 2019

Efficacy and optimal timing of sivelestat in critically ill patients with COVID-19: a multicenter retrospective

Qi Zhang1,2, Yijie Liu2, Bowen Ran2,3,4

  • 1Beijing University of Chinese Medicine, Beijing, 100105, China.

BMC Pulmonary Medicine
|June 24, 2026
PubMed

Insights

Sivelestat may improve survival in severe COVID-19 patients. This retrospective study found sivelestat associated with reduced 28-day mortality in intensive care unit patients, suggesting a potential therapeutic benefit.

Area of Science:

  • Critical Care Medicine
  • Pharmacology
  • Infectious Diseases

Background:

  • Cytokine storm is key in severe COVID-19 progression.
  • Sivelestat exhibits anti-inflammatory properties.
  • Sivelestat is a potential therapeutic for severe COVID-19.

Purpose of the Study:

  • To evaluate sivelestat's efficacy in severe COVID-19 patients.
  • To assess the impact of sivelestat on mortality and secondary outcomes.

Main Methods:

  • Multicenter retrospective study in China.
  • Involved intensive care unit patients with severe COVID-19.
  • 1:2 propensity score matching (PSM) used for analysis.

Main Results:

  • Sivelestat associated with improved 28-day survival (53.55% vs. 40.87%, P=0.03).
  • No significant differences in secondary outcomes observed.
  • Early sivelestat administration linked to reduced mortality.

Conclusions:

  • Sivelestat use may reduce 28-day mortality in severe COVID-19 ICU patients.
  • Sivelestat shows promise as a treatment for severe COVID-19.
Abstract

Keywords:
ICUPrognosisPropensity score matchingSevere COVID-19Sivelestat

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: